BLOOD REVIEWS

Scope & Guideline

Advancing the frontiers of Hematology and Oncology.

Introduction

Welcome to the BLOOD REVIEWS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of BLOOD REVIEWS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0268-960x
PublisherCHURCHILL LIVINGSTONE
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1987 to 2024
AbbreviationBLOOD REV / Blood Rev.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressJOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND

Aims and Scopes

BLOOD REVIEWS is dedicated to advancing knowledge in the field of hematology through comprehensive reviews that synthesize current research, clinical practices, and emerging therapies. The journal emphasizes the integration of clinical and laboratory science, aiming to provide a platform for critical insights into both common and rare hematological disorders.
  1. Hematological Malignancies:
    The journal covers a wide range of hematological malignancies including leukemia, lymphoma, and myeloma, focusing on their biology, treatment strategies, and patient management.
  2. Coagulation Disorders:
    Research on various coagulation disorders, such as hemophilia, thrombocytopenia, and thrombotic conditions, is a key focus, including novel therapeutic approaches and management strategies.
  3. Transfusion Medicine:
    Exploration of transfusion practices, adverse reactions, and the evolving landscape of transfusion-related therapies, including the use of blood products and their clinical implications.
  4. Immunotherapy and Targeted Therapies:
    Significant emphasis on the development and application of immunotherapies, CAR T-cell therapy, and targeted treatments in hematological disorders, reflecting the shift towards personalized medicine.
  5. Patient-Centered Care:
    The journal highlights the importance of quality of life, patient preferences, and shared decision-making in treatment approaches for hematological diseases.
  6. Emerging Technologies:
    Coverage of innovative technologies such as artificial intelligence and genomics in the diagnosis and treatment of hematological conditions, aiming to integrate cutting-edge science into clinical practice.
BLOOD REVIEWS is witnessing an evolution in its research focus, with several themes gaining traction. These emerging topics reflect the latest advancements and ongoing challenges in the field of hematology.
  1. Gene Therapy and Genetic Modulation:
    There is a growing interest in gene therapy as a potential curative approach for various hematological disorders, including sickle cell disease and hemophilia, highlighting advancements in genetic technologies.
  2. Microbiome and Hematology:
    Research on the gut microbiome's role in hematological conditions is on the rise, exploring how dysbiosis may impact disease progression and treatment outcomes, indicating a shift towards understanding systemic influences on hematologic health.
  3. Immunotherapy Innovations:
    The emergence of novel immunotherapeutic strategies, including bispecific antibodies and checkpoint inhibitors, is a significant trend, reflecting the ongoing transformation in treatment paradigms for hematological malignancies.
  4. Health Equity and Access to Care:
    Increasing publications focus on disparities in hematological care, emphasizing the need for equity in access to innovative therapies, particularly among diverse populations.
  5. Patient-Reported Outcomes and Quality of Life:
    There is an increasing emphasis on patient-reported outcomes and quality of life measures in research, underscoring the importance of holistic approaches to patient care in hematology.
  6. Artificial Intelligence in Hematology:
    The application of artificial intelligence and machine learning in diagnostics, treatment personalization, and monitoring of hematologic diseases is an emerging theme, indicative of the journal's forward-looking approach.

Declining or Waning

While BLOOD REVIEWS continues to explore a diverse array of topics, certain areas have seen a decrease in focus or publication frequency. This may reflect shifts in research priorities or advancements in understanding that have led to saturation in some themes.
  1. Traditional Chemotherapy Approaches:
    With the rise of targeted therapies and immunotherapies, traditional chemotherapy approaches for hematological malignancies are discussed less frequently, as newer treatments gain prominence.
  2. Basic Hematology:
    Fundamental topics in hematology that do not directly relate to clinical or translational research are becoming less common, as the journal increasingly favors articles with direct clinical applications or innovative methodologies.
  3. Epidemiological Studies:
    While still important, epidemiological studies focusing on rare conditions or those with limited translational impact are less frequently published, as the journal prioritizes studies that offer immediate clinical relevance.
  4. Classic Diagnostic Techniques:
    The focus on traditional diagnostic methods is waning in favor of more advanced techniques, such as genomic profiling and machine learning applications in diagnostics.
  5. Older Treatment Modalities:
    The exploration of older treatment modalities, particularly those that have been largely replaced by newer therapies, is less common as the field moves toward more effective and innovative treatment options.

Similar Journals

Hematology

Elevating Hematology: A Platform for Cutting-Edge Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

Blood Advances

Empowering Researchers in Blood Advances
Publisher: ELSEVIERISSN: 2473-9529Frequency: 24 issues/year

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

TRANSFUSION

Exploring New Frontiers in Blood Donation and Transfusion
Publisher: WILEYISSN: 0041-1132Frequency: 12 issues/year

TRANSFUSION is a prestigious peer-reviewed journal published by WILEY, dedicated to advancing the field of hematology and transfusion medicine. With an ISSN of 0041-1132 and an E-ISSN of 1537-2995, this journal serves as a vital resource for researchers and professionals alike, delivering high-quality studies and reviews that impact clinical practice and blood management strategies. The journal enjoys a strong reputation, evidenced by its impressive Q1 ranking in hematology and Q2 in both immunology and allergy as of 2023. Covering foundational aspects from 1958 to 2024, TRANSFUSION not only provides valuable insights but also fosters collaboration and innovation in understanding the complexities of blood donation, transfusion practices, and immunological responses. With its significant contributions to the scientific community, this journal is essential for those seeking to stay at the forefront of research and advancements in transfusion science.

Blood Research

Advancing Hematological Science for a Healthier Tomorrow
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

HemaSphere

Unveiling the latest in hematologic breakthroughs.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Journal of Hematology

Bridging Knowledge Gaps in Hematology
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

Asian Journal of Transfusion Science

Empowering research in hematology and immunology.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0973-6247Frequency: 2 issues/year

Asian Journal of Transfusion Science, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, is a prominent open-access journal dedicated to the interdisciplinary fields of hematology and immunology. With an ISSN of 0973-6247 and E-ISSN 1998-3565, it serves as a crucial platform for researchers, clinicians, and students from around the globe, facilitating the dissemination of high-quality, peer-reviewed research. Established in 2007, the journal has consistently aimed to advance scientific knowledge in transfusion practices, enhancing patient care and safety in transfusion medicine. Despite its recent categorization in the Q4 quartile within both Hematology and Immunology, the journal is making strides toward greater visibility in the academic community, with plans for expanded reach and increased citation impact. With its commitment to open-access publishing, the Asian Journal of Transfusion Science ensures that invaluable research findings are readily accessible to all stakeholders, thereby bolstering collaborative efforts in transfusion science and related disciplines.

TRANSFUSION AND APHERESIS SCIENCE

Empowering Research for Enhanced Patient Outcomes in Hematology
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 1473-0502Frequency: 6 issues/year

TRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.

Hematology-American Society of Hematology Education Program

Advancing Hematology through Expert Education
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Lancet Haematology

Elevating patient care with groundbreaking discoveries.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.